Shared on 04 Nov 25

Fair value Decreased 1.26%

Narrative Update: Analyst Price Target for Olympus Adjusted Analysts have slightly reduced their fair value estimate for Olympus, lowering the price target from $1,976.43 to $1,951.54. The change is attributed to updated expectations for discount rates and revenue growth.

Shared on 21 Oct 25

Fair value Decreased 1.50%

Narrative Update on Olympus Analysts have adjusted the fair value estimate for Olympus downward by approximately $30, reflecting updated views on key financial assumptions. What's in the News Olympus completed a share buyback of 20,766,200 shares, representing 1.84 percent, for ¥37,034.97 million between July and September 2025 (Key Developments).

Shared on 18 Sep 25

Fair value Decreased 5.33%

The consensus price target for Olympus has been revised downward, primarily reflecting a modest decrease in both the company’s future P/E ratio and discount rate, resulting in a lower fair value estimate of ¥2006. What's in the News Olympus launched the VISERA S OTV-S500 imaging platform in the U.S., integrating advanced diagnostic features for ENT and urology with enhanced image quality, compatibility, and content management capabilities.

Shared on 27 Aug 25

Fair value Decreased 2.24%

The slight reduction in Olympus’s analyst price target reflects modest declines in both consensus revenue growth and net profit margin forecasts. What's in the News Olympus lowered fiscal year 2026 guidance, with revenue expected at ¥998,000 million (previously ¥999,000 million), operating profit at ¥136,000 million (previously ¥150,000 million), and profit attributable to owners of parent at ¥94,000 million (previously ¥105,000 million).